Literature DB >> 6196562

Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release.

M R Bristow, N E Kantrowitz, W D Harrison, W A Minobe, W S Sageman, M E Billingham.   

Abstract

We tested the hypothesis that cardiac histamine release mediates subacute doxorubicin (DXR) cardiotoxicity in rabbits. New Zealand white rabbits given DXR 20 mg/kg i.v. over 30 min developed myocardial damage 24 h later that was similar to that observed in humans. In isolated heart preparations, DXR produced dose-related cardiac histamine release at DXR concentrations of 1, 5, and 25 micrograms/ml given as 1-min exposures. Prior exposure of isolated hearts to 10 microM cromolyn sodium completely prevented histamine release from 5 micrograms/ml DXR. Pretreatment of animals with cromolyn produced significant protection against DXR-mediated subacute cardiotoxicity. We conclude that the release of cardiac histamine may be involved in the pathogenesis of anthracycline cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196562     DOI: 10.1097/00005344-198311000-00002

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  PLCδ1 protein rescues ischemia-reperfused heart by the regulation of calcium homeostasis.

Authors:  Soyeon Lim; Woochul Chang; Min-Ji Cha; Byeong-Wook Song; Onju Ham; Se-Yeon Lee; Changyoun Lee; Jun-Hee Park; Sang-Kyou Lee; Yangsoo Jang; Ki-Chul Hwang
Journal:  Mol Ther       Date:  2014-03-18       Impact factor: 11.454

2.  Evidence for the lack of involvement of free radicals in adriamycin-induced histamine release from rat peritoneal cells.

Authors:  L Candussio; F Bartoli Klugmann; G Decorti; L Baldini
Journal:  Agents Actions       Date:  1988-04

3.  H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study.

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Richard A Kronmal; Joao A Lima; David D Ralph; Corey E Ventetuolo; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2014-11

4.  H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program.

Authors:  Peter J Leary; Edward Hess; Anna E Barón; Kelley R Branch; Gaurav Choudhary; Catherine L Hough; Bradley A Maron; David D Ralph; John J Ryan; Ryan J Tedford; Noel S Weiss; Roham T Zamanian; Tim Lahm
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

5.  Histamine H2 Receptor Antagonists, Left Ventricular Morphology, and Heart Failure Risk: The MESA Study.

Authors:  Peter J Leary; Ryan J Tedford; David A Bluemke; Michael R Bristow; Susan R Heckbert; Steven M Kawut; Eric V Krieger; Joao A Lima; Carolina S Masri; David D Ralph; Steven Shea; Noel S Weiss; Richard A Kronmal
Journal:  J Am Coll Cardiol       Date:  2016-04-05       Impact factor: 24.094

6.  Interaction of adriamycin with rat and mouse mast cells: histamine release and cellular uptake.

Authors:  G Decorti; F B Klugmann; L Candussio; L Baldini
Journal:  Agents Actions       Date:  1989-04

Review 7.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

8.  Non-immunological release of histamine from rat mast cells elicited by antineoplastic agents.

Authors:  L M Botana; E Arnaez; M R Vieytes; A Alfonso; M J Bujan; M C Louzao; A Cabado
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Protective effects of fructose-1,6-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats.

Authors:  R Danesi; N Bernardini; A Marchetti; M Bernardini; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo.

Authors:  F B Klugmann; G Decorti; L Candussio; V Grill; F Mallardi; L Baldini
Journal:  Br J Cancer       Date:  1986-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.